Hypercholesterolemia
Conditions
Keywords
LDL cholesterol reduction, AI-guided prescriptions, Dietary supplements, Personalized nutrition
Brief summary
The trial compared AI-guided and standard physician-guided dietary supplement (DS) prescriptions for lowering LDL cholesterol (LDL-C) in hypercholesterolemic patients. The AI system used genetic, metabolic, and clinical data to personalize DS regimens, hypothesizing superior efficacy over traditional methods. This 3-month randomized, controlled trial involved adults aged 40-75 with specific LDL-C levels, excluding those with significant health risks. Participants were divided into a control group with physician-guided DS and an AI-guided group. The AI system from Triangel Scientific provided dynamic, personalized recommendations. Baseline and follow-up measurements included lipid profiles and adherence assessments. The AI-guided group showed significantly greater LDL-C reduction and improvement in other lipid markers. The study concluded that AI-guided DS prescriptions are more effective, suggesting a promising future for AI in personalized cholesterol management.
Interventions
OTHERStandart supplementation therapy group
Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
OTHERAI-guided supplementation therapy group
Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Sponsors
Center of New Medical Technologies
S.LAB (SOLOWAYS)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 40 and 75 years. * LDL-C level between 70 and 190 mg/dL, confirmed in at least two sequential checks conducted within the last six months prior to signing the consent form.
Exclusion criteria
* Personal history of cardiovascular disease or high risk (≥ 20%). * Triglycerides (TG) ≥ 400 mg/dL. * Body Mass Index (BMI) ≥ 35 kg/m² * Use of lipid-lowering drugs or supplements affecting lipid metabolism within the last three months. * Diabetes mellitus. * Known severe or uncontrolled thyroid, liver, renal, or muscle diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in LDL-C | 180 days |
Secondary
| Measure | Time frame |
|---|---|
| Percent change in high-sensitivity C-reactive protein ( | 180 days |
| Percent change in high-density lipoprotein cholesterol | 180 days |
| Percent change in total cholesterol. | 180 days |
| Percent change in serum triglycerides between the groups. | 180 days |
Countries
Russia
Outcome results
None listed